Strategies for the assessment of protein aggregates in pharmaceutical biotech product development

Pharm Res. 2011 Apr;28(4):920-33. doi: 10.1007/s11095-010-0297-1. Epub 2010 Oct 23.

Abstract

Within the European Immunogenicity Platform (EIP) ( http://www.e-i-p.eu ), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods should be used during product development and make recommendations to the biotech community with regard to strategies for their application during the development of protein therapeutics.

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / immunology*
  • Biotechnology / methods*
  • Biotechnology / standards
  • Drug Contamination / prevention & control*
  • Drug Discovery / methods*
  • Drug Discovery / standards
  • European Union
  • Guidelines as Topic
  • Immunoassay
  • Protein Folding
  • Quality Control
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / immunology*
  • Technology, Pharmaceutical / methods*
  • Technology, Pharmaceutical / standards

Substances

  • Antibodies, Monoclonal
  • Recombinant Proteins